Again, clarity will come when the trial protocol is posted, but it sure sounds like “weekly” dosing here and I suspect AFTER the 3-4 week cycle of TAS-102 and Bevacizumab. I don’t think DrJ would have rolled over for going cold turkey as happened after 2 doses of Leronlimab in the severe/critical COVID study. A strong clinical argument can be made to maintain CCR5 receptor occupancy after the chemo regimen completes…DrJ knows this. These are clinical people at the table both with Cytodyn and the FDA who understand the mechanism of action of each drug and the role it plays in treatment.

“TAS-102 and bevacizumab will be administered for three of four weeks in a four-week cycle, and leronlimab (at doses of 350 mg or 700 mg) will be administered weekly. ”